Standard BioTools Future Growth
Future criteria checks 1/6
Standard BioTools is forecast to grow earnings and revenue by 8.1% and 16.4% per annum respectively while EPS is expected to grow by 4.8% per annum.
Key information
8.1%
Earnings growth rate
4.8%
EPS growth rate
| Life Sciences earnings growth | 26.4% |
| Revenue growth rate | 16.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Jan 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 140 | -69 | N/A | -81 | 2 |
| 12/31/2025 | 118 | -84 | N/A | -87 | 2 |
| 12/31/2024 | 99 | -100 | N/A | -91 | 4 |
| 12/31/2023 | 84 | -111 | N/A | -113 | 4 |
| 9/30/2023 | 82 | -130 | -122 | -117 | N/A |
| 6/30/2023 | 101 | -141 | -139 | -134 | N/A |
| 3/31/2023 | 95 | -139 | -144 | -138 | N/A |
| 12/31/2022 | 98 | -109 | -106 | -101 | N/A |
| 9/30/2022 | 102 | -83 | -96 | -92 | N/A |
| 6/30/2022 | 80 | -92 | -75 | -70 | N/A |
| 3/31/2022 | 86 | -82 | -46 | -42 | N/A |
| 12/31/2021 | 82 | -88 | -44 | -40 | N/A |
| 9/30/2021 | 87 | -73 | -27 | -23 | N/A |
| 6/30/2021 | 81 | -39 | -13 | -11 | N/A |
| 3/31/2021 | 68 | -45 | -22 | -21 | N/A |
| 12/31/2020 | 56 | -53 | -29 | -28 | N/A |
| 12/31/2019 | 32 | -57 | -51 | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 76X0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 76X0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 76X0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 76X0's revenue (16.4% per year) is forecast to grow faster than the German market (4.5% per year).
High Growth Revenue: 76X0's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 76X0's Return on Equity is forecast to be high in 3 years time